AMPH vs LGND
AMPH: Amphastar manufactures technically complex generic and proprietary injectable, inhalation, and intranasal drugs with high barriers to entry, leveraging proprietary formulation and manufacturing capabilities to compete in high-margin, supply-constrained markets. LGND: Ligand Pharmaceuticals is a biotechnology firm that generates recurring revenue through royalty interests and the licensing of proprietary drug formulation technologies to pharmaceutical partners.
Side-by-side fundamentals
| Metric | AMPH | LGND | Edge |
|---|---|---|---|
| Price as of 2026-07-30 close | $20.38 | $297.50 | |
| Market cap as of 2026-07-31 | $899M | $5.8B | |
| P/E as of 2026-07-31 | 12.22 | 37.64 | AMPH lower |
| PEG as of 2026-07-31 | -1.77 | 1.25 | AMPH lower |
| Net margin as of 2026-07-31 | +11.0% | +56.0% | LGND higher |
| Gross margin as of 2026-07-31 | +47.3% | +95.3% | LGND higher |
| Operating margin as of 2026-07-31 | +16.2% | +34.5% | LGND higher |
| ROE as of 2026-07-31 | +10.2% | +16.2% | LGND higher |
| ROA as of 2026-07-31 | +4.8% | +11.1% | LGND higher |
| Debt / equity as of 2026-07-31 | 0.79 | 0.45 | LGND lower |
| Revenue growth (YoY) as of 2026-07-31 | -1.4% | +51.2% | LGND higher |
| Revenue CAGR (3y) SEC XBRL | +13.0% | +11.0% | AMPH higher |
| Dividend streak (yrs) SEC XBRL | n/a | 1 | |
| Beta as of 2026-07-31 | 0.72 | 1.18 | |
| 1-year return as of 2026-07-30 close | -4.5% | +119.0% | LGND higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.